Literature DB >> 12860745

French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers.

X Mariette1, D Salmon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12860745      PMCID： PMC1754631          DOI： 10.1136/ard.62.8.791

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  29 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.

Authors:  Stefania Girlanda; Paola Mantegani; Elena Baldissera; Patrizia Aiello; Manuela Ratti; Maria Grazia Sabbadini; Claudio Fortis
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

Review 3.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 4.  Immunosuppression related to collagen-vascular disease or its treatment.

Authors:  Carol Dukes Hamilton
Journal:  Proc Am Thorac Soc       Date:  2005

5.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Authors:  F Tubach; D Salmon; P Ravaud; Y Allanore; P Goupille; M Bréban; B Pallot-Prades; S Pouplin; A Sacchi; R M Chichemanian; S Bretagne; D Emilie; M Lemann; O Lortholary; O Lorthololary; X Mariette
Journal:  Arthritis Rheum       Date:  2009-07

6.  Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.

Authors:  Patricio Escalante; Kirstin J Kooda; Rizwana Khan; San San Aye; Stratos Christianakis; Daniel G Arkfeld; Glenn R Ehresmann; Jens J Kort; Brenda E Jones
Journal:  Lung       Date:  2014-10-16       Impact factor: 2.584

7.  Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.

Authors:  Boksoon Chang; Hye Yun Park; Kyeongman Jeon; Joong Kyong Ahn; Hoon-Suk Cha; Eun-Mi Koh; Eun-Suk Kang; Won-Jung Koh
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

8.  Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Authors:  Yesim Ozguler; Gulen Hatemi; Serdal Ugurlu; Emire Seyahi; Melike Melikoglu; Sermin Borekci; Ersan Atahan; Gul Ongen; Vedat Hamuryudan
Journal:  Rheumatol Int       Date:  2016-10-03       Impact factor: 2.631

9.  Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.

Authors:  Jérémie Sellam; Haifa Hamdi; Carine Roy; Gabriel Baron; Marc Lemann; Xavier Puéchal; Maxime Breban; Francis Berenbaum; Marc Humbert; Karin Weldingh; Dominique Salmon; Philippe Ravaud; Dominique Emilie; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.